TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6395321
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75 mg/kg/day
Study: 26947697
Drug: Propylbetaine‐polihexanide (PP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylbetaine‐polihexanide (PP) solution (Prontosan)
Study: 26947697
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) solution
Study: 11696205
Drug: Indomethacin (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.7 mg/kg, t.i.d.)
Study: 3241272
Drug: Aerobic (lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic (lactate threshold) exercise therapy for 10 weeks
Study: 29189426
Drug: Lifestyle physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle physical activity (moderate physical activity during routine daily activities)
Study: 26265447
Drug: CryoSeal® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CryoSeal® (5 ml per ITA bed)
Study: 20941948
Drug: Chitosan-containing spray
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan-containing spray (1% concentration, low molecular chitosan, degree of deacetylation 87%)
Study: 20941948
Drug: Chitosan-free control
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan-free control (vehicle only) spray
Study: 18371465
Drug: MC-1 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1 (250 mg/d)
Study: 14750576
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment starting at 40 mg/day, tapered by 5 mg every 2 weeks for 16 weeks
Study: 8766365
Drug: Pharmacotherapy during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy during psychotherapy stages
Study: 8766365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pharmacotherapy and psychotherapy
Study: 2012511
Drug: Prednisone 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.3 mg/kg
Study: 2012511
Drug: Prednisone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.75 mg/kg
Study: 6802095
Drug: Phosphate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate therapy
Study: 12351551
Drug: G1/G2 sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: G1/G2 sequential culture system for 5 days
Study: 7669385
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (batch 1)
Study: 7669385
Drug: DTP vaccine
Normalized name: DTP Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP vaccine (batches 2 and 3)
Study: 7362083
Drug: Fenoterol hydrobromide
Normalized name: Fenoterol hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol hydrobromide (Berotec) 0.1% solution, 60 micrograms per nostril every six hours
Study: 7362083
Drug: Fenoterol hydrobromide
Normalized name: Fenoterol hydrobromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol hydrobromide (Berotec) 0.1% solution, doubled dosage
Study: 6341684
Drug: Chlorthalidone, 100
Normalized name: Chlorthalidone, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 100 mg/day for 6 weeks
Study: 29912604
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2000 mg/day)
Study: 27741174
Drug: Enoxaparin plus
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin plus Aspirin (4,000 IU enoxaparin + 100 mg aspirin)
Study: 27741174
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (100 mg aspirin)
Study: 25474427
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg indomethacin
Study: 25474427
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (ASA)
Study: 25474427
Drug: No antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiplatelet therapy (non-ASA)
Study: 18581020
Drug: Fast-track group
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track group (continuous infusion of fentanyl and propofol, atracurium one hour later)
Study: 18581020
Drug: Conventional extubation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional extubation group (bolus doses of fentanyl and pancuronium)
Study: 15858063
Drug: Yohimbine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (selective alpha2‐adrenoceptor antagonist)
Study: 7018051
Drug: Cinoxacin 250
Normalized name: cinoxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin 250 mg four times a day (QID)
Study: 7018051
Drug: Cinoxacin 500
Normalized name: cinoxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin 500 mg twice a day (BID)
Study: 8238122
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU of oxytocin in 20 ml of normal saline solution
Study: 8238122
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of normal saline solution (placebo)
Study: 26609282
Drug: Ashwagandha (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha (300 mg twice daily)
Study: 15334426
Drug: Lumiracoxib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumiracoxib 100 mg twice daily
Study: 16888080
Drug: SHiDo chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHiDo chemotherapy
Study: 12741348
Drug: Menotropin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menotropin treatment for three months (Group A)
Study: 12741348
Drug: Menotropin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menotropin treatment starting three months after surgery (Group B)
Study: 1411848
Drug: Single-day split
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-day split dose of 1.6 g of metronidazole
Study: 1411848
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g dose of tinidazole
Study: 29106665
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks (NIVO3)
Study: 29106665
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses (NIVO1+IPI3)
Study: 29106665
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks for 4 doses (NIVO3+IPI1)
Study: 18263997
Drug: Breast health
Normalized name: Ascorbic Acid/Bioflavonoid/Broccoli/Curcumin/Flaxseed/Genistein/Selenium 100 MG-50 MG-85 MG-300 MG-200 MG-10 MG-0.1 MG Oral Tablet [PROHERBS BREAST HEALTH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast health messages administered by salon stylists
Study: 16080872
Drug: Triptorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (3.75 mg injected intramuscularly every 28 days for 3 months)
Study: 16080872
Drug: Leuprorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin (3.75 mg injected subcutaneously every 28 days for 3 months)
Study: 12435290
Drug: CVAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVAP + docetaxel (100 mg/m2)
Study: 7577853
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg danazol daily (n = 17)
Study: 7577853
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg gestrinone twice weekly (n = 19)
Study: 7682931
Drug: Scopolamine (0.25‐0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.25‐0.75 mg, intramuscular)
Study: 7682931
Drug: Scopolamine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.50 and 0.75 mg, intramuscular)
Study: 29996980
Drug: PRPFM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRPFM treatment group
Study: 26086792
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin 2 mg daily
Study: 24296517
Drug: High-dose calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcium lactate (300 mg · kg(‐1) body mass)
Study: 24296517
Drug: Low-dose calcium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose calcium lactate (150 mg · kg(‐1) body mass)
Study: 22728514
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of intestinal microbiota from lean donors
Study: 22728514
Drug: Autologous microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous microbiota infusion
Study: 20508469
Drug: Thermogenic drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermogenic drink (TD) - 336 mL daily
Study: 20508469
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) - 336 mL daily
Study: 12627313
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (3 x 500 mg tablets daily for 7 days prior to race and 150 mg/l in carbohydrate beverages during race)
Study: 12627313
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 tablets daily for 7 days prior to race and no vitamin C in carbohydrate beverages during race)
Study: 8291920
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus MPL (10 mg/kg)
Study: 5787671
Drug: LB46, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB46, 0.5 mg by oral administration
Study: 5787671
Drug: Propranolol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 20 mg
Study: 29467598
Drug: Spirulina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina extract (1500 mg for 6 weeks)
Study: 26595965
Drug: Intravenous laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous laser irradiation in addition to traditional medicamental therapy (Group 2)
Study: 26595965
Drug: Laser skin
Normalized name: NIACINAMIDE 0.6 mg in 120 mL TOPICAL LIQUID [Miracle Laser Skin Mist]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser skin treatment (Group 3)
Study: 26595965
Drug: Traditional medicamental
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medicamental therapy alone (Control Group 1)
Study: 17070147
Drug: Aggressive LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive LDL-C reduction (goal <70 mg/dL)
Study: 17070147
Drug: Standard LDL-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard LDL-C reduction (goal <100 mg/dL)
Study: 13677262
Drug: Combined immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined immunosuppressive treatment (antithymocyte globulin, methylprednisolone, and cyclosporine)
Study: 10021716
Drug: Porcine surfactant
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine surfactant prophylaxis (200 mg/kg endotracheally)
Study: 3691610
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg trimetazidine (single dose)
Study: 3691610
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg trimetazidine (chronic administration, three times a day)
Study: 27468128
Drug: High-fructose diet
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose diet (HFrD) (+3.5 g fructose/kg fat-free mass per day) for 7 days
Study: 24296342
Drug: Facial exercises
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Facial exercises (daily training for 7 weeks)
Study: 19004053
Drug: Etanercept (TNF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (TNF-alpha antagonist)
Study: 16648318
Drug: Olanzapine (5‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5‐15 mg/day)
Study: 12511713
Drug: HDM allergen
Normalized name: American house dust mite allergenic extract 6 SQ-HDM / European house dust mite allergenic extract 6 SQ-HDM [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM allergen inhalation
Study: 10368793
Drug: Nasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal salmon calcitonin (200 IU daily for 2 months, followed by a 2-month pause, repeated for 3 cycles) and 500 mg calcium daily
Study: 2053087
Drug: Tenoxicam administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam administered at 8 am or 12 pm
Study: 2053087
Drug: Tenoxicam administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam administered at midday
Study: 6754331
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g palatinite
Study: 31071535
Drug: Intramuscular hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hypertonic saline injection to the vastus medialis
Study: 31071535
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection (sham)
Study: 22087795
Drug: Brown seaweed
Normalized name: seaweed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) 500 mg
Study: 19063686
Drug: PTH(1-34) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-34) treatment for 1 year
Study: 19063686
Drug: PTH(1-34) treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH(1-34) treatment
Study: 10833696
Drug: Telephone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone therapy (10 sessions of 30 minutes each)
Study: 22163281
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (100, 400, 4000 µg per day) for 6 months
Study: 19459233
Drug: Higher support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher support (phone coaching plus monthly exercise support group)
Study: 15353377
Drug: Routine individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine individual therapy
Study: 10665618
Drug: Physostigmine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (24 mg/d and 30 mg/d)
Study: 3093918
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor therapy
Study: 30486630
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with Inj. Cisplatin 100 mg/m2 for three-weekly and EBRT with 60 Co/LINAC and photon radiation of 70 Gy in 35 fractions for 7 weeks.
Study: 30486630
Drug: Chemo boost
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo boost with Inj. Cisplatin 6 mg/m2 on last 15 fractions of treatment and EBRT with 60 Co/LINAC photon radiation of 70 Gy in 35 fractions for 7 weeks.
Study: 23768683
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment for 12 weeks
Study: 22169050
Drug: Acetaminophen (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (300 mg) with codeine (30 mg)
Study: 17065897
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg) administered preventively with electrical stimulation
Study: 17065897
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg) administered in parallel to remifentanil infusion
Study: 11134918
Drug: Counselling (CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling (CBT or psychodynamic approach) in addition to usual GP treatment
Study: 11134918
Drug: Usual GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual GP treatment (Control)
Study: 9362434
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg as a 2-hour infusion monthly for 2 years
Study: 1397827
Drug: Monthly journal
Normalized name: Journavx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly journal club sessions with two didactic sessions before the club started.
Study: 4029557
Drug: Gastric distention
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric distention (0, 250, 500, or 750 ml of air for 15 min)
Study: 30400122
Drug: Meditation (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation (45 minutes daily for 6 weeks)
Study: 20156072
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet plus weight-reducing drugs when necessary
Study: 17934150
Drug: Prandial premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prandial premixed therapy (PPT) - lispro mix 50/50 (50% insulin lispro protamine suspension and 50% lispro); n = 187
Study: 17934150
Drug: Basal/bolus therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal/bolus therapy (BBT) - glargine at bedtime plus mealtime lispro; n = 187
Study: 6890839
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation (40 mg isosorbide dinitrate as retard formulation)
Study: 28828764
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin 0.5 units per drop 4 times per day (QID)
Study: 28828764
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin 1 unit per drop 4 times per day (QID)
Study: 28828764
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin 2 units per drop 4 times per day (QID)
Study: 26998724
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 150 mg daily for 8 weeks
Study: 23787192
Drug: En-masse retraction
Normalized name: Salazopyrin EN
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: En-masse retraction with mini-implants
Study: 11981084
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 15 mg/day orally
Study: 11981084
Drug: Methylcobalamin 500
Normalized name: methylcobalamin 500 mcg oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin 500 mg intravenously after each HD, in addition to folic acid
Study: 11981084
Drug: Vitamin B(6)
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B(6) 60 mg/day orally, in addition to folic acid and methylcobalamin
Study: 8575497
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg finasteride for 1 year, then 5 mg finasteride for 4 years
Study: 8575497
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride for the entire 5 years
Study: 28107680
Drug: Buprenorphine Treatment
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Treatment
Study: 25646328
Drug: PNPLA3 G-allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNPLA3 G-allele carriers
Study: 19478295
Drug: 6-month naltrexone
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month naltrexone implant
Study: 17092597
Drug: Unmodified human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unmodified human insulin
Study: 17092597
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart and unmodified human insulin
Study: 3126306
Drug: Praziquantel 20-40
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel 20-40 mg kg‐1
Study: 3126306
Drug: Praziquantel 30-40
Normalized name: praziquantel 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 30-40 mg kg‐1
Study: 3126306
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of praziquantel
Study: 30412630
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not receiving low molecular weight heparin)
Study: 20536800
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (n = 31)
Study: 20536800
Drug: Cold therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold therapy (n = 29)
Study: 15536472
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg soybean‐derived pinitol, twice daily for 13 weeks
Study: 11531789
Drug: Ointment (O)
Normalized name: Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment (O)
Study: 11531789
Drug: Cream (C)
Normalized name: Oral Cream
DrugBank: Coffea arabica seed, roasted (DB15603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream (C)
Study: 11531789
Drug: Solution (S)
Normalized name: Irrigation Solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution (S)
Study: 11531789
Drug: Low-viscosity cream
Normalized name: polyethylene terephthalate (intrinsic viscosity 0.40-0.70)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-viscosity cream (LVC)
Study: 9257795
Drug: rhuMAb‐E25 (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuMAb‐E25 (0.15 mg/kg subcutaneously, 0.15 mg/kg intravenously, or 0.5 mg/kg intravenously)
Study: 9257795
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous and intravenous)
Study: 8501148
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist plus estrogen-progestin add-back regimen
Study: 8501148
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist plus progestin add-back regimen
Study: 3327939
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with protein-free artificial surfactant (ALEC)